Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Our CEO sounds very confident.I like the term "LAUNCH TEAM"
put together ,and adding more for FX,and the future of Zanerba.
Its kind of coincidental we just saw another perfect FX launch a couple of days ago.Falcon X, now FXS launch is on the pad.
Excellent presentation yesterday.
http://wsw.com/webcast/jeff126/zyne/index.aspx
Snake,nothing personal,but please reframe from posting to me any more.
At 8.49 am this morning I gave you the answer,TIME & DATE with this post.
I only posted about 3 times back to you when the presentation was.
I noticed the presentation is after the bell. You think we will hear anything that might excite the market in the morning.
Here it is Snake.
tem 8.01 Other Events
On June 2, 2020, Zynerba Pharmaceuticals, Inc. (the “Company”) posted on its website a slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.
It will be the slide show of the presentation today.
No worries mate.It's all good.
It’s under the “investors” link on their website.
I bet it is regarding the Jefferies presentation this afternoon.
It says on June 2nd they posted a new slide presentation on their website.
It’s dated June 2nd and speaks to the presentation. Which is tomorrow? Is that correct?
Snake,the only 8 k I see was filled May 27
What’s this new 8K all about this morning?
If you look out of the window in the rocket
you can see BIZARROW WORLD waving goodbye...
33 Stocks Moving in Tuesday's Pre-Market Session
7:04 am ET June 2, 2020 (Benzinga) Print
Gainers
Inpixon (NASDAQ: INPX) rose 43% to $2.03 in pre-market trading as traders circulate a recent USA Today article titled "Tech cruise ships could implement to combat spread of coronavirus: far-UVC sanitation, contact tracing." It mentioned Inpixon's CEO.
MoneyGram International, Inc (NASDAQ: MGI) shares rose 41.7% to $3.67 in pre-market trading on Bloomberg report that Western Union is looking to buy the company.
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 40.2% to $3.10 in pre-market trading after jumping around 32% on Monday.
Marathon Patent Group, Inc. (NASDAQ: MARA) shares rose 30.1% to $0.95 in pre-market trading.
Riot Blockchain, Inc. (NASDAQ: RIOT) rose 15% to $2.61 in pre-market trading after gaining 6% on Monday.
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) rose 13.2% to $6.25 in pre-market trading after gaining 5% on Monday.
Canaan Inc. (NASDAQ: CAN) rose 11.8% to $2.37 in pre-market trading after declining over 10% on Monday.
American Virtual Cloud Technologies, Inc. (NASDAQ: AVCT) rose 10.8% to $1.95 in pre-market trading after gaining 10% on Monday.
Iterum Therapeutics plc (NASDAQ: ITRM) rose 10.6% to $1.88 in pre-market trading. RBC Capital downgraded Iterum Therapeutics from Outperform to Sector Perform and lowered the price target from $7 to $2. Iterum Therapeutics shares tumbled 60% on Monday after the company reported topline results for a Phase 3 clinical trial of oral and IV sulopenem in complicated urinary tract infection.
China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) rose 10.3% to $1.50 in pre-market trading. China Jo-Jo Drugstores shares dropped 47% on Monday after the company reported a $10 million registered direct offering.
Sasol Limited (NYSE: SSL) rose 10.2% to $6.50 in pre-market trading after surging around 15% on Monday.
Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) rose 9.5% to
Thought I'd post this interview with Zanerba CEO,I'm sure
all longs have seen.
We've come a long way...
https://video.search.yahoo.com/yhs/search?fr=yhs-omr-001&hsimp=yhs-001&hspart=omr&p=zanerba+news#id=4&vid=fee77a000d24c90dbdf91cd688a74684&action=click
I think it was a
drive - by ,just trying to get me worked up. LOL
You're right
I'm not the right guy to ask
Maybe you are not the right guy to answer this, but why is the info on the page so old? 2017 with no updates? I know there is no moderator, just wondering what happened with some of the clinical trials.
OT; I wanna see a Tesla pick up on the moon. lol
I wonder how much longer it will be before Elon catches a ride on the Dragon..
OK...Ready to go into ZANERBA MODE.From looks of things
this could become one of the most interesting weeks in some time with the recent options market behavior.Close eye on tomarrow mornings pre market.
Look forward to Jefferies presentation Tue.Also DEES guidence from FDA,and last ,but not least FX results in June hopefully.
GLTA
Yes. Was good to see!!
OT;Hope evryone had a chance to watch the Dragon launch yesterday,and docking today. WOW! Congrats to Elon and NASA. WELCOME BACK TO SPACE USA!
Ok gang,a new game...name the "option day"
I'm naming it the "BIG BANG TWO"
Exactly Stockfun.
IT kind of goes back to the pullback from 16.00,
and evidently how those trial results got viwed by some that brought on several law ferms openg their doors to class actions.I have no idea if any reached a court of law or if any are pending.
I personally read that result as VERY positive,and a lot of people in this business agreed,yet we see what happened.I just really get a knot in my stomac when I see that type of stuff.I named it months ago 'BIZARROW WOLD SYNDROME" LOL
Its turned into a gift IMO.One that seldom comes along in the market.
We are now within days of knowing for sure if indeed its been a gift.
GL TY Brother,and all Zanerbians
Amen to that brother. The way I see it dhbuzz.....If you do all as you’ve said I think it’s much more likely to work out and if it doesn’t.....well, then I don’t blame myself. I figure It just wasn’t meant to be. Sometimes God just has another plan..
Future news...FDA news on DEES direction.
June 2 presentation
and of course Phase 3 FX Top Line results
...and anything else that may pop up,lol
yes,the float is a big deal for me too,and also the fact ZANERBA has enough cash on hand to get all trials finished.Like we know the p3 FX results are huge,as it seals the deal for NDA.
The options action may be an indication Zanerba is right on the verge of a really big breakout.
The news on the options looks great and I love that low float.
Snake,LOL...I got a little off track.I think it was the news about options..
Man that gets your attention.Next week could get reeeeeeeeeeeeeeeal interesting.
It takes 22,000 years to travel one light year ,ok enough of that.LOL
I think my numbers are off on that last post.....
The most interesting
Closing thought....
It takes 20,000 years for light to reach earth that's one light year away. Hubble has been able to see a galaxy that is 13.1 billion light years away.
So 20,000 x 13.1 billion=THAT IS SOME VERY OLD LIGHT. LOL
NASA hopes to launch a new telescope in 2021 thats 10x more powerful than hubble.
Are we getting closer to seeing the outer edges of the BIG BANG???
Wonder what is beyond that...
HMMMMMMMM MORE INTERESTING...
https://www.americanbankingnews.com/2020/05/28/zynerba-pharmaceuticals-nasdaqzyne-pt-raised-to-24-00.html
I did a lot of day trading in 80s,90s,into 2000 got out in 2008,and back in
about 2010.One big thing Ive leaned,dont bet money on dreams,and trust nothing said,or that cant show a good track record history.
Go with FACTS,top to bottom...and how much you can afford to lose.If it does not work out there is usually no one to blame but yourself.
If ZANERBA does not go as I hope,Ill get out of the market again for a while. lol
I feel the exact same way. This is really not speculation as speculation goes. Good luck to you as well buddy.
Stockfun.I can say in all honesty
that the time Ive been in the market about 35 years,Ive never been envolved with a stock at this price that has the credentials,and past history this one does, and when I say credentials,IM talking about management,& Doctors and so on,low flot,cash on hand,no debt.
The history is speaking for itself...phase 2 ASD RESULTS ... EXCELENT
fx phase 1 results GOOD
fx phase 2 results...BETTER
FX PHASE 3 RESULTS,,,STAY TUNED
Now Ive been involved with a lot of stocks whos middle name was'speculating'lol,but ZANERBA SPECULATING is educated speculationg....not pie in the sky speculating...BIG DIFFERENCE
GL MY FRIEND
Thanks dhbuzz. I enjoy speculating as well. So glad to be in on the ground of something great.
I know I'm repeating myself
but the FX syndrome phase 3 results are huge to the fact it will give companies that may be interested coming on board or offering for buy out a clear picture of revenue.Again I would assume there are people waiting to see.
Going back to touch on your question Stockfun.
I actually think Zanerba could reach that point in less time,if they are not bought out first.
I'll take these odds every day.This is like playing poker,and knowing what cards everyone else has,or at least being 90% sure...lol
FXS Results will be what this industry ,and the market need for final
justification on many fronts.Though Zanerba shares are presently held
by 47 % institutions,is a very respetful number,when FX trial results are released,if positive,then even more big dogs get in long term.
There is also the industry to consider,as I think there have to be other eyes watching,and for several reasons,not for just what zygel looks to be doing,but the manner it is being delivered into the body.The patents Zanebra holds are HUGE speaking to this.For example ,lets take GW and epidiolex,and GW thinks that Trans dermal could be a better means of their drug delivery.Just a colaboration between Zanerba ,and GW on that alone could be huge.
Bottom line though is we wait for FX news,and speculate the odds,phase 1,and 2 went well...my bet is 3 did too.
Not wanting to put the cart before the horse,but
looking to perhaps start hearing more company info,or outside writers talking about how zygel may be able to replace 2,or 3 other drugs a patient may be using.Creating a huge saving for insurance companies.
Followers
|
91
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2676
|
Created
|
08/06/15
|
Type
|
Free
|
Moderators |
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Company is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. The Company intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome. The Company's ZYN002 is synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. ZYN002 is being developed as a clear that is designed to provide controlled drug delivery with once- or twice-daily dosing. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through a patch. The Company intends to test the ZYN001 patch for application to the arm, back and thigh. The Company intends to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.
Corporate Profile |
Zynerba (NASDAQ: ZYNE) is pioneering the development of patent-protected, next-generation synthetic cannabinoid therapeutics formulated for transdermal delivery. Its two lead product candidates in development include ZYN002 and ZYN001, which are being evaluated in five indications. ZYN002 is the first and only synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. In June 2016, the company initiated the STAR 1 Phase 2 clinical trial in refractory epilepsy patients and in August 2016, initiated the STOP Phase 2 clinical trial in patients with osteoarthritis of the knee. A Phase 2 clinical trial in patients with Fragile X syndrome will be initiated in the second half of 2016.
ZYN001, a prodrug of THC that enables transdermal delivery through the skin and circulatory system via a patch, is in preclinical development. A Phase 1 clinical trial is planned in the first half of 2017.
In August 2015, Zynerba completed an initial public offering, raising net proceeds of $42.1 million. As of June 30, 2016, cash and cash equivalents totaled $32.1 million, which is projected to fund five Phase 2 clinical trials through 2017.
EPS (TTM) | 9/30/2016 | -2.47 |
---|---|
P/E Ratio | 9/30/2016 | -- |
Market Cap | Micro Cap | 146M |
Shares Outstanding | 9.95M |
Float | 7.2M |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |